This report comes with 10% free customization, enabling you to add data that meets your specific business needs.
The neoantigen cancer vaccine market is projected to reach $1,988.5 million by 2031 from $35.5 million in 2024, at a compound annual growth rate (CAGR) of 77.73%.
Market Report Coverage - Neoantigen Cancer Vaccine
Market Segmentation
- Product Type - Personalized and Off-the-Shelf
- Type of Neovaccine - Nucleic Acid Vaccine, Peptide Vaccine, and Dendritic Cell-Based Vaccine
- Therapeutic Specialty - Lung Cancer, Urinary System Cancer, Melanoma, Liver Cancer, Head and Neck Cancer, and Blood and Bone Marrow Cancer
- Line of Therapy - First Line, Second Line, and Later Lines
Regional Segmentation
- North America - U.S. and Canada
- Europe - Germany, U.K., France, Italy, and Spain
- Asia-Pacific and Middle East - China, Australia, Japan, South Korea, and Israel
Market Growth Drivers
- Increasing Global Prevalence of Cancer
- Increase in Adoption of Personalized Medicine to Tailor Patient’s Treatment on an Individual Level
- Significant External Funding for Executing Research and Development Exercise
Market Challenges
- Higher Cost of Personalized Cancer Vaccines
- Hurdles in Clinical Development and Optimization Process
- Uncertain Reimbursement Scenario
- Payer Uncertainty and Outcome-Based Pricing
- High Capital Requirement Hampering the Expansion of Global Reach
Market Opportunities
- Treatment Gaps
- Reduced Turnaround Time and Cost
- Partnerships and Collaboration between Various Healthcare Stakeholders
- Data Analytics
Key Companies Profiled
Moderna Therapeutics, F. Hoffmann-La Roche Ltd, AstraZeneca plc, Agenus, OSE Immunotherapeutics, Advaxis, Medigene, Neon Therapeutics (Acquired by BioNTech SE), Genocea Biosciences, Immunovative Therapies, Gritstone Oncology, Nouscom, NantBioScience, Immunovaccine, BioLineRx, Geneos Therapeutics
Key Questions Answered in the Report
- What are the major market drivers, challenges, and opportunities in the global neoantigen cancer vaccines market?
- What are the underlying structures resulting in emerging trends within the global neoantigen cancer vaccines market?
- What key development strategies are implemented by the major players in order to sustain in the competitive market?
- What are the key regulatory implications in developed and developing regions for neoantigen cancer vaccines?
- Who are the leading players with significant offerings to the global neoantigen cancer vaccines market? What is the expected market dominance for each of these leading players?
- Which companies are anticipated to be highly disruptive in the future and why?
- What are the current treatment gaps, and how neovaccines are expected to fill these gaps?
- What are the unmet needs in the global neoantigen cancer vaccine market?
Market Overview
The global neoantigen cancer vaccine industry analysis projects the market to grow at a significant CAGR of 77.73% during the forecast period 2024-2031. The neoantigen cancer vaccine market is expected to generate $35.5 million in revenue in 2024, owing to the expected launch of the first neoantigen vaccine, DC vaccine in the market.
The neoantigen cancer vaccine market growth has been primarily attributed to major drivers in this market, such as rising prevalence of cancers, increasing adoption of personalized medicine to tailor patient’s treatment on an individual level, and significant external funding for executing research and development exercises. However, significant challenges are restraining the market growth. These challenges include the expected higher cost of personalized cancer vaccines, hurdles in clinical development, and payer uncertainty and outcome-based pricing.
Expert Quote on the Neoantigen Cancer Vaccine Market
“The real issues with neovaccines are higher cost, turn-around times, and limited efficacy. The cost and time to manufacture have come down in the last four years, and as technology improves, it will come down more.”
The neoantigen cancer vaccine market report provides a holistic view of the market in terms of various factors influencing it, including reported clinical findings, financing and partnership opportunities, expected market, and current clinical landscape.
The scope of this report is centered upon conducting a detailed study of the products expected to be allied with the oncology market. In addition, the study also includes exhaustive information on the unmet needs, perception on the new products, competitive landscape, market share of key players, growth potential of each underlying sub segment and company, as well as other vital information with respect to the global neoantigen cancer vaccine market.
Pipeline Segmentation
- The emerging neoantigen cancer vaccines are segmented based on product type into personalized and off-the-shelf neovaccines.
- The emerging neoantigen cancer vaccines are segmented based on disease/application into lung cancer, urinary system cancer, melanoma, liver cancer, head and neck cancer, and blood and bone marrow cancer.
- The emerging neoantigen cancer vaccines are segmented based on type of neovaccine into nucleic acid vaccine, peptide vaccine, and dendritic cell vaccine.
- The emerging neoantigen cancer vaccines are segmented based on line of therapy into first, second, and later lines therapy.
- The emerging neoantigen cancer vaccines are segmented based on development phase into Phase I, II, and III.
- The emerging neoantigen cancer vaccines are segmented on the basis of route-of-administration into intradermal, subcutaneous, and intramuscular administrations.
Table of Contents
1 Product Definition
1.1 Inclusion and Exclusion
2 Research Scope
2.1 Scope of the Study
2.2 Key Questions Answered in the Report
3 Research Methodology
3.1 Primary Data Sources
3.1.1 Secondary Data Sources
3.2 Market Estimation Model
3.2.1 Factors for Data Prediction and Modelling
3.2.2 Assumptions and Limitations
4 Neoantigen Cancer Vaccine in Cancer Immunotherapy: Overview
4.1 Introduction
4.2 Cancer Antigens
4.3 Targeting Cancer Neoantigen: A Next Wave of Innovation in Oncology?
4.4 Neoantigen Cancer Vaccine Mechanism of Action
4.5 Types of Neoantigen Cancer Vaccine (by Product Type)
4.5.1 Personalized Cancer Vaccine
4.5.2 Off-the-Shelf Neoantigen Cancer Vaccine
4.6 Types of Neoantigen Cancer Vaccine Market (by Type of Neovaccine (Biological Platform))
4.6.1 Nucleic Acid/DNA/mRNA Vaccine
4.6.2 Peptide Vaccine
4.6.3 Dendritic Cell-Based Vaccine
4.7 Types of Neoantigen Cancer Vaccine (by Type of Delivery)
4.7.1 Lipid-Based Delivery Approaches
4.7.1.1 Peptide (SLP) Mediate Vaccine Delivery in Conjunction with an Adjuvant
4.7.1.2 Sequential Immunization of Viral Prime and RNA Boost
4.7.2 Direct Injection of Unformulated mRNA Vaccines Encoding Neoepitopes
4.7.3 Other Approaches
4.8 Prediction Software for Neoantigens
4.8.1 Limitations of Neoantigen Prediction Process
4.9 Limitations of Neoantigen Cancer Vaccine
4.9.1 Lower Tumor Mutational Burden
4.9.2 Neoantigens Maturity
4.1 Future Prospects
4.10.1 Multi-Epitope Vaccination
4.10.2 Combinatorial Regimen with Targeted Therapies
4.10.3 Combinatorial Regimen with Conventional Cancer Therapies
5 Industry Insights
5.1 Overview of Regulatory Pathway for Neoantigen Cancer Vaccine
5.1.1 U.S. FDA Guidelines for Biologics License Application (BLA) Submission
5.1.2 European Medicine Agency (EMA) Biologics License Application Process
5.1.2.1 Centralized Procedure
5.1.2.2 Decentralized Procedure
5.1.2.3 Mutual-Recognition Procedure
5.2 Regulatory Challenges
5.3 Successful Regulatory Strategies
5.4 Patent Landscape
6 Impact of COVID-19 on the Global Neoantigen Cancer Vaccine Market
7 Market Dynamics
7.1 Overview
7.2 Emerging and Current Market Trends
7.3 Market Drivers
7.3.1 Increasing Global Prevalence of Cancer
7.3.2 Increase in Adoption of Personalized Medicine to Tailor Patient’s Treatment on an Individual Level
7.3.3 Significant External Funding for Executing Research and Development Exercise
7.4 Market Restraints
7.4.1 Higher Cost of Personalized Cancer Vaccines
7.4.2 Hurdles in Clinical Development and Optimization Process
7.4.3 Uncertain Reimbursement Scenario
7.4.4 Payer Uncertainty and Outcome-Based Pricing
7.4.5 High Capital Requirement Hampering the Expansion of Global Reach
7.5 Market Opportunities
7.5.1 Treatment Gaps
7.5.2 Reduced Turnaround Time and Cost
7.5.3 Partnerships and Collaboration between Various Healthcare Stakeholders
7.5.4 Data Analytics
8 Pipeline Landscape
8.1 Emerging Neoantigen Cancer Vaccine
8.2 Clinical Trials Heat Map
8.3 Pipeline Analysis
8.3.1 By Development Phase
8.3.2 By Type of Therapy
8.3.3 By Product Type
8.3.4 By Treatment Strategy
8.3.5 By Type of Neovaccine
8.3.6 By Delivery Approach
8.3.7 By Line of Therapy
8.3.8 By Therapeutic Specialty
8.3.9 By Route of Administration
8.3.10 By Core Product Status
8.3.11 By Neoantigen Payload
9 Global Neoantigen Cancer Vaccine Market (by Product Type)
9.1 Personalized Neoantigen Cancer Vaccine
9.2 Off-the-Shelf Neoantigen Cancer Vaccine
10 Global Neoantigen Cancer Vaccine Market (by Pipeline Product)
10.1 Tedopi
10.2 Allovax
10.3 DC (Dendritic Cells) Vaccine
10.4 ADXS-Neo
10.5 GEN-009
10.6 RG6180
11 Global Neoantigen Cancer Vaccine Market (by Type of Neovaccine)
11.1 Nucleic Acid (DNA/RNA Vaccine)
11.1.1 DNA Vaccine
11.1.2 RNA Vaccine
11.2 Peptide Vaccines
11.3 Dendritic Cell-Based Vaccine
12 Global Neoantigen Cancer Vaccine Market (by Line of Therapy)
12.1 First Line Neovaccine Regimens
12.2 Second Line Neovaccine Regimens
12.3 Later Lines Neovaccine Regimens
13 Global Neoantigen Cancer Vaccine Market (by Therapeutic Specialty), 2024-2031
13.1 Melanoma
13.2 Lung Cancer
13.3 Urinary System Cancer
13.4 Liver Cancer
13.5 Head and Neck Cancer
13.6 Blood and Bone Marrow Cancer
14 Global Neoantigen Cancer Vaccine Market (by Region)
14.1 Overview
14.2 North America
14.3 U.S.
14.3.1 Market Size and Forecast
14.4 Canada
14.4.1 Market Size and Forecast
14.5 Europe
14.5.1 Germany
14.5.1.1 Market Size and Forecast
14.5.2 France
14.5.2.1 Market Size and Forecast
14.5.3 U.K.
14.5.3.1 Market Size and Forecast
14.5.4 Italy
14.5.4.1 Market Size and Forecast
14.5.5 Spain
14.5.5.1 Market Size and Forecast
14.6 Asia-Pacific and Middle East
14.6.1 Japan
14.6.1.1 Market Size and Forecast
14.6.2 China
14.6.2.1 Market Size and Forecast
14.6.3 Australia
14.6.3.1 Market Size and Forecast
14.6.4 South Korea
14.6.4.1 Market Size and Forecast
14.6.5 Israel
14.6.5.1 Market Size and Forecast
15 Competitive Landscape
15.1 Overview
15.2 Key Developments and Strategies
15.2.1 Partnerships and Alliances
15.2.2 Business Expansions
15.2.3 Merger and Acquisition Activities
15.2.4 Product Approvals
15.2.5 Financing Activities
15.2.6 Funding Activities
15.2.7 Regulatory and Legal Activities
16 Company Profiles
16.1 Moderna Therapeutics
16.1.1 Company Overview
16.1.2 Role of Moderna Therapeutics in the Global Neoantigen Cancer Vaccine Market
16.1.3 Technology and Capabilities
16.1.4 Financials
16.1.5 Key Insights about Financial Health of the Company
16.1.6 SWOT Analysis:
16.2 F. Hoffmann-La Roche Ltd
16.2.1 Company Overview
16.2.2 Role of F. Hoffmann-La Roche Ltd in the Global Neoantigen Cancer Vaccine Market
16.2.3 Technology and Capabilities
16.2.3.1 Technology Platform
16.2.3.2 Manufacturing
16.2.4 Financials
16.2.5 Key Insights about Financial Health of the Company
16.2.6 SWOT Analysis:
16.3 AstraZeneca plc
16.3.1 Company Overview
16.3.2 Role of AstraZeneca plc in the Global Neoantigen Cancer Vaccine Market
16.3.3 Financials
16.3.4 Key Insights about Financial Health of the Company
16.3.5 SWOT Analysis:
16.4 Agenus
16.4.1 Company Overview
16.4.2 Role of Agenus in the Global Neoantigen Cancer Vaccine Market
16.4.3 Technology and Capabilities
16.4.3.1 Technology Platforms
16.4.3.2 Manufacturing
16.4.3.3 Adjuvant
16.4.4 Financials
16.4.5 Key Insights about Financial Health of the Company
16.4.6 SWOT Analysis:
16.5 OSE Immunotherapeutics
16.5.1 Company Overview
16.5.2 Role of OSE Immunotherapeutics in the Global Neoantigen Cancer Vaccine Market
16.5.3 Technology and Capabilities
16.5.3.1 Technology Platforms
16.5.3.2 Manufacturing
16.5.4 Financials
16.5.5 Key Insights about Financial Health of the Company
16.5.6 SWOT Analysis:
16.6 Advaxis
16.6.1 Company Overview
16.6.2 Role of Advaxis in the Global Neoantigen Cancer Vaccine Market
16.6.3 Technology and Capabilities
16.6.3.1 Technology platform
16.6.3.2 Manufacturing
16.6.4 Financials
16.6.5 Key Insights about Financial Health of the Company
16.6.6 SWOT Analysis:
16.7 Medigene
16.7.1 Company Overview
16.7.2 Role of Medigene in the Global Neoantigen Cancer Vaccine Market
16.7.3 Technology and Capabilities
16.7.3.1 Technology Platform
16.7.3.2 Manufacturing
16.7.4 Financials
16.7.5 Key Insights about Financial Health of the Company
16.7.6 SWOT Analysis:
16.8 Neon Therapeutics (Acquired by BioNTech SE)
16.8.1 Company Overview
16.8.2 Role of Neon Therapeutics (Acquired by BioNTech SE) in the Global Neoantigen Cancer Vaccine Market
16.8.3 Technology and Capabilities
16.8.3.1 Technology Platforms
16.8.3.2 Manufacturing
16.8.4 SWOT Analysis:
16.9 Genocea Biosciences
16.9.1 Company Overview
16.9.2 Role of Genocea Biosciences in the Global Neoantigen Cancer Vaccine Market
16.9.3 Technology and Capabilities
16.9.3.1 Technology Platform
16.9.3.2 Manufacturing Capabilities
16.9.4 SWOT Analysis:
16.1 Immunovative Therapies
16.10.1 Company Overview
16.10.2 Role of Immunovative Therapies in the Global Neoantigen Cancer Vaccine Market
16.10.3 Technology and Capabilities
16.10.3.1 Technology Platform
16.10.3.2 Manufacturing
16.10.4 SWOT Analysis:
16.11 Gritstone Oncology
16.11.1 Company Overview
16.11.2 Role of Gritstone Oncology in the Global Neoantigen Cancer Vaccine Market
16.11.3 Technology and Capabilities
16.11.3.1 Technology Platform
16.11.3.2 Manufacturing
16.11.4 SWOT Analysis:
16.12 Nouscom
16.12.1 Company Overview
16.12.2 Role of Nouscom in the Global Neoantigen Cancer Vaccine Market
16.12.3 Technology and Capabilities
16.12.3.1 Technology Platform
16.12.3.2 Manufacturing
16.12.4 SWOT Analysis:
16.13 NantBioScience
16.13.1 Company Overview
16.13.2 Role of NantBioScience in the Global Neoantigen Cancer Vaccine Market
16.13.3 SWOT Analysis:
16.14 Immunovaccine
16.14.1 Company Overview
16.14.2 Role of Immunovaccine in the Global Neoantigen Cancer Vaccine Market
16.14.3 SWOT Analysis:
16.15 BioLineRx
16.15.1 Company Overview
16.15.2 Role of BioLineRx in the Global Neoantigen Cancer Vaccine Market
16.15.3 SWOT Analysis:
16.16 Geneos Therapeutics
16.16.1 Company Overview
16.16.2 Role of Geneos Therapeutics in the Global Neoantigen Cancer Vaccine Market
16.16.3 SWOT Analysis
List of Figures
Figure 1: Impact Analysis of Market Drivers and Market Restraints on the Global Neoantigen Cancer Vaccine Market
Figure 2: Global Neoantigen Cancer Vaccine Market Size (by Product Type), $Million, 2024 and 2031
Figure 3: Global Neoantigen Cancer Vaccine Market (by Type of Neovaccine), $Million, 2024 and 2031
Figure 4: Global Neoantigen Cancer Vaccine Market (by Therapeutic Specialty), $Million, 2024 and 2031
Figure 5: Global Neoantigen Cancer Vaccine Market (by Line of Therapy), $Million, 2024 and 2031
Figure 6: Global Neoantigen Cancer Vaccine Market (by Region), $Million, 2024 and 2031
Figure 7: Global Neoantigen Cancer Vaccine Market Segmentation
Figure 8: Global Neoantigen Cancer Vaccine Market: Existing Pipeline Segmentation
Figure 9: Global Neoantigen Cancer Vaccine Market Research Methodology
Figure 10: Primary Research Methodology
Figure 11: Bottom-Up Approach (Segment-Wise Analysis)
Figure 12: Step by Step Approach
Figure 13: Step by Step Process for Neoantigen Vaccine Development
Figure 14: Type of Cancer Antigens
Figure 15: Specialized Therapies Segmentation in the U.S.
Figure 16: Neoantigen Cancer Vaccine Mechanism of Action
Figure 17: Factors Affecting Neoantigen Prediction Process
Figure 18: Future Prospects of Neovaccines
Figure 19: U.S. FDA Review Timeline
Figure 20: EMA Review Timeline
Figure 21: Share of Patents (by Ownership), 2016-2019
Figure 22: Number of Deaths Due to Different Cancer Types, Million, 2020
Figure 23: Global Cancer Incidence, Million, 2018
Figure 24: Neovaccines Funding and Expansion Activities Breakout, January 2016-September 2019
Figure 25: Overall Financing Raised by Emerging Neovaccine Companies, $Million, January 2016-September 2019
Figure 26: Overview of Reimbursement Policies in Europe
Figure 27: Market Opportunities
Figure 28: Key Neoantigen Cancer Vaccine in Clinical Development Phase I, II and III, 2021
Figure 29: Neoantigen Cancer Vaccine: Clinical Trials Heat Map
Figure 30: Neoantigen Cancer Vaccine: Breakdown of Pipeline (by Development Phase), 2021
Figure 31: Neoantigen Cancer Vaccine (by Type of Therapy)
Figure 32: Neoantigen Cancer Vaccine (by Product Type)
Figure 33: Neoantigen Cancer Vaccine (by Treatment Strategy)
Figure 34: Neoantigen Cancer Vaccine (by Type of Neovaccine (Biological Platform))
Figure 35: Neoantigen Cancer Vaccine (by Delivery Approach)
Figure 36: Neoantigen Cancer Vaccine, by Line of Therapy
Figure 37: Number of Neoantigen Cancer Vaccine (by Oncology Speciality)
Figure 38: Neoantigen Cancer Vaccine (by Route of Administration)
Figure 39: Neoantigen Cancer Vaccine (by Core Product Status)
Figure 40: Neoantigen Cancer Vaccine (by Neoantigen Payload)
Figure 41: Revenue Contribution of Different Segments (by Product Type), $Million, 2024 and 2031
Figure 42: Personalized Neoantigen Cancer Vaccine Market (by Product Type), $Million, 2024-2031
Figure 43: Off-the-Shelf Neoantigen Cancer Vaccine Market (by Product Type), $Million, 2024-2031
Figure 44: Revenue Contribution of Different Segments (by Pipeline), $Million, 2024 and 2031
Figure 45: Tedopi-Neoantigen Cancer Vaccine Market (by Pipeline), $Million, 2024-2031
Figure 46: Allovax-Neoantigen Cancer Vaccine Market (by Pipeline), $Million, 2024-2031
Figure 47: DC (Dendritic Cells) Vaccine-Neoantigen Cancer Vaccine Market (by Pipeline), $Million, 2024-2031
Figure 48: ADXS-Neo-Neoantigen Cancer Vaccine Market (by Pipeline), $Million, 2024-2031
Figure 49: GEN-009-Neoantigen Cancer Vaccine Market (by Pipeline), $Million, 2024-2031
Figure 50: RG6180-Neoantigen Cancer Vaccine Market (by Pipeline), $Million, 2024-2031
Figure 51: Revenue Contribution of Different Segments (by Type of Neovaccine), $Million, 2024 and 2031
Figure 52: DNA-Based Neoantigen Cancer Vaccine Market (Nucleic Acid, by Type of Neovaccine), $Million, 2024-2031
Figure 53: RNA-Based Neoantigen Cancer Vaccine Market (Nucleic Acid, by Type of Neovaccine), $Million, 2024-2031
Figure 54: Peptide Neoantigen Cancer Vaccine Market (by Type of Neovaccine), $Million, 2024-2031
Figure 55: Dendritic Cell-Based Neoantigen Cancer Vaccine Market (by Type of Neovaccine), $Million, 2024-2031
Figure 56: Revenue Contribution of Different Segments (by Line of Therapy), $Million, 2024 and 2031
Figure 57: First Line Neoantigen Cancer Vaccine Market (by Line of Therapy), $Million, 2024-2031
Figure 58: Second Line Neoantigen Cancer Vaccine Market (by Line of Therapy), $Million, 2024-2031
Figure 59: Later Lines Neoantigen Cancer Vaccine Market (by Line of Therapy), $Million, 2024-2031
Figure 60: Melanoma Neoantigen Cancer Vaccine Market (by Therapeutic Specialty), $Million, 2024-2031
Figure 61: Lung Neoantigen Cancer Vaccine Market (by Therapeutic Specialty), $Million, 2024-2031
Figure 62: Urinary System Neoantigen Cancer Vaccine Market (by Therapeutic Specialty), $Million, 2024-2031
Figure 63: Liver Neoantigen Cancer Vaccine Market (by Therapeutic Specialty), $Million, 2024-2031
Figure 64: Head and Neck Neoantigen Cancer Vaccine Market (by Therapeutic Specialty), $Million, 2024-2031
Figure 65: Blood and Bone Marrow Neoantigen Cancer Vaccine Market (by Therapeutic Specialty), $Million, 2024-2031
Figure 66: Global Neoantigen Cancer Vaccine Market (by Region)
Figure 67: Global Neoantigen Cancer Vaccine Market (by Region), $Million, 2024 and 2031
Figure 68: Global Neoantigen Cancer Vaccine Market (by Region), $Million, 2024-2031
Figure 69: North America: Market Dynamics
Figure 70: North America Neoantigen Cancer Vaccine Market, $Million, 2024-2031
Figure 71: North America Neoantigen Cancer Vaccine Revenue Contribution (by Country), $Million, 2024 and 2031
Figure 72: Projections of the Older Adult Population in the U.S., Million, 2016-2060
Figure 73: U.S. Neoantigen Cancer Vaccine Market, $Million, 2024-2031
Figure 74: Canada Neoantigen Cancer Vaccine Market, $Million, 2024-2031
Figure 75: Europe: Market Dynamics
Figure 76: Europe Neoantigen Cancer Vaccine Market, $Million, 2024-2031
Figure 77: Europe Neoantigen Cancer Vaccine Revenue Contribution (by Country), $Million, 2024 and 2031
Figure 78: Germany Neoantigen Cancer Vaccine Market, $Million, 2024-2031
Figure 79: France Neoantigen Cancer Vaccine Market, $Million, 2024-2031
Figure 80: U.K. Neoantigen Cancer Vaccine Market, $Million, 2024-2031
Figure 81: Italy Neoantigen Cancer Vaccine Market, $Million, 2024-2031
Figure 82: Spain Neoantigen Cancer Vaccine Market, $Million, 2024-2031
Figure 83: Asia-Pacific: Market Dynamics
Figure 84: Asia-Pacific Neoantigen Cancer Vaccine Market, $Million, 2024-2031
Figure 85: Asia-Pacific and Middle East Revenue Contributions of Various Countries, $Million, 2024 and 2031
Figure 86: Japan Neoantigen Cancer Vaccine Market, $Million, 2024-2031
Figure 87: China Neoantigen Cancer Vaccine Market, $Million, 2024-2031
Figure 88: Australia Neoantigen Cancer Vaccine Market, $Million, 2024-2031
Figure 89: South Korea Neoantigen Cancer Vaccine Market, $Million, 2024-2031
Figure 90: Israel Neoantigen Cancer Vaccine Market, $Million, 2024-2031
Figure 91: Share of Key Developments and Strategies, January 2016-November 2021
Figure 92: Partnerships and Alliances (by Company), January 2016-November 2021
Figure 93: Business Expansions (by Company), January 2016-November 2021
Figure 94: Merger and Acquisition Activities (by Company), January 2016-November 2021
Figure 95: Product Approvals (by Company), January 2016-November 2021
Figure 96: Financing Activities (by Company), January 2016-November 2021
Figure 97: Funding Activities (by Company), January 2016-November 2021
Figure 98: Regulatory and Legal Activities (by Company), January 2016-November 2021
Figure 99: Moderna Therapeutics: Technology and Capabilities
Figure 100: Moderna Therapeutics: Therapeutic Focus Segmentation
Figure 101: Moderna Therapeutics: Overall Financials/Revenue, $Million, 2018-2020
Figure 102: Moderna Therapeutics.: R&D Expenditure, $Million, 2018-2020
Figure 103: Moderna Therapeutics: SWOT Analysis
Figure 104: F. Hoffmann-La Roche Ltd: Overall Product Portfolio
Figure 105: F. Hoffmann-La Roche Ltd: Overall Financials/Revenue, $Billion, 2018-2020
Figure 106: F. Hoffmann-La Roche Ltd: Revenue (by Segment), $Billion, 2018-2020
Figure 107: F. Hoffmann-La Roche Ltd: Revenue (by Region), $Billion, 2018-2020
Figure 108: F. Hoffmann-La Roche Ltd: R&D Expenditure, $Billion, 2018-2020
Figure 109: F. Hoffmann-La Roche Ltd: SWOT Analysis
Figure 110: AstraZeneca plc: Therapeutic Focus Segmentation
Figure 111: AstraZeneca plc: Overall Financials/Revenue, $Billion, 2018-2020
Figure 112: AstraZeneca plc: Net Revenue (by Region), $Billion, 2018-2020
Figure 113: AstraZeneca plc: R&D Expenditure, $Billion, 2018-2020
Figure 114: AstraZeneca plc: SWOT Analysis
Figure 115: Agenus: Technology and Capabilities (as Per Type of Product)
Figure 116: Agenus: Therapeutic Focus Segmentation
Figure 117: Agenus: Overall Financials/Revenue, $Million, 2018-2020
Figure 118: Agenus: R&D Expenditure, $Million, 2018-2020
Figure 119: Agenus: SWOT Analysis
Figure 120: OSE Immunotherapeutics: Therapeutic Focus Segmentation
Figure 121: OSE Immunotherapeutics: Overall Financials/Revenue, $Million, 2018-2020
Figure 122: OSE Immunotherapeutics: R&D Expenditure, $Million, 2016-2018
Figure 123: OSE Immunotherapeutics: SWOT Analysis
Figure 124: Advaxis: Therapeutic Focus Segmentation
Figure 125: Advaxis: Overall Financials/Revenue, $Million, 2018-2020
Figure 126: Advaxis: R&D Expenditure, $Million, 2018-2020
Figure 127: Advaxis: SWOT Analysis
Figure 128: Medigene: Therapeutic Focus Segmentation
Figure 129: Medigene: Overall Financials/Revenue, $Million, 2018-2020
Figure 130: Medigene: R&D Expenditure, $Million, 2018-2020
Figure 131: Medigene: SWOT Analysis
Figure 132: Neon Therapeutics: Therapeutic Focus Segmentation (Available From FY2019)
Figure 133: Neon Therapeutics (Acquired by BioNTech): SWOT Analysis
Figure 134: Genocea Biosciences: Therapeutic Focus Segmentation
Figure 135: Genocea Biosciences: SWOT Analysis
Figure 136: Immunovative Therapies: SWOT Analysis
Figure 137: Gritstone Oncology: Therapeutic Focus Segmentation
Figure 138: Gritstone Oncology: SWOT Analysis
Figure 139: Nouscom: Therapeutic Focus Segmentation (Available from FY2019)
Figure 140: Nouscom: SWOT Analysis
Figure 141: NantBioScience: SWOT Analysis
Figure 142: Immunovaccine: SWOT Analysis
Figure 143: BioLineRx: SWOT Analysis
Figure 144: Geneos Therapeutics: SWOT Analysis
List of Tables
Table 1: Implications of Personalized Cancer Vaccines (PCVs)
Table 2: Implications of Off-the-Shelf Neoantigen Cancer Vaccine
Table 3: Implications of DNA and RNA Vaccines
Table 4: Implications of Peptide Vaccine
Table 5: Implications of Dendritic Cell Vaccine
Table 6: Prediction Software Utilized by Various Companies
Table 7: Neoantigen Cancer Vaccines Patent Landscape, by 2019
Table 8: Neoantigen Cancer Vaccine (by Type of Therapy)
Table 9: Neoantigen Cancer Vaccine (by Line of Therapy)
Table 10: Neoantigen Cancer Vaccine (by Route of Administration)
Table 11: Neoantigen Cancer Vaccine (by Core Product Type (Licensed Products/ Technology Only))
Table 12: Neoantigen Cancer Vaccine (by Neoantigen Payload)
Table 13: Neoantigen Cancer Vaccine for Melanoma: Pipeline Products
Table 14: Neoantigen Cancer Vaccine for Lung Cancer: Pipeline Products
Table 15: Neoantigen Cancer Vaccine for Urinary Cancer: Pipeline Products
Table 16: Neoantigen Cancer Vaccine for Head and Neck Cancer: Pipeline Products
Table 17: Neoantigen Cancer Vaccine for Blood and Bone Marrow Cancer: Pipeline Products
Samples
LOADING...
Companies Mentioned
- Moderna Therapeutics
- F. Hoffmann-La Roche Ltd
- AstraZeneca plc
- Agenus
- OSE Immunotherapeutics
- Advaxis
- Medigene
- Neon Therapeutics
- Genocea Biosciences
- Immunovative Therapies
- Gritstone Oncology
- Nouscom
- NantBioScience
- Immunovaccine
- BioLineRx
- Geneos Therapeutics
